Terms: = Brain cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
70 results:
1. PROTAC ezh2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
Shi MX; Ding X; Tang L; Cao WJ; Su B; Zhang J
BMC Cancer; 2024 Apr; 24(1):504. PubMed ID: 38644473
[TBL] [Abstract] [Full Text] [Related]
2. PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
Brown EJ; Balaguer-Lluna L; Cribbs AP; Philpott M; Campo L; Browne M; Wong JF; Oppermann U; Carcaboso ÁM; Bullock AN; Farnie G
Sci Rep; 2024 Jan; 14(1):328. PubMed ID: 38172189
[TBL] [Abstract] [Full Text] [Related]
3. Ribosomal S6 protein kinase 4 promotes resistance to ezh2 inhibitors in glioblastoma.
Pang F; Zhang L; Li M; Yi X; Wang Y; Yang P; Wen B; Jiang J; Teng Y; Yang X; Chen L; Xu J; Wang L
Cancer Gene Ther; 2023 Dec; 30(12):1636-1648. PubMed ID: 37726387
[TBL] [Abstract] [Full Text] [Related]
4. Targeting ezh2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
[TBL] [Abstract] [Full Text] [Related]
5. ezh2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
[TBL] [Abstract] [Full Text] [Related]
6. Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma.
Quddusi DM; Bajcinca N
IET Syst Biol; 2023 Aug; 17(4):143-161. PubMed ID: 37277696
[TBL] [Abstract] [Full Text] [Related]
7. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or ezh2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
[TBL] [Abstract] [Full Text] [Related]
8. Targeting B7‑H3 through ezh2 inhibition in MYC‑positive Group 3 medulloblastoma.
Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
[TBL] [Abstract] [Full Text] [Related]
9. Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Liao X; Li Z; Zheng H; Qian W; Zhang S; Chen S; Li X; Tang M; Xu Y; Yu R; Li M; Song L; Li J
Mol Cancer Res; 2023 Jul; 21(7):648-663. PubMed ID: 36961398
[TBL] [Abstract] [Full Text] [Related]
10. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Perwein T; Giese B; Nussbaumer G; von Bueren AO; van Buiren M; Benesch M; Kramm CM
J Neurooncol; 2023 Feb; 161(3):525-538. PubMed ID: 36720762
[TBL] [Abstract] [Full Text] [Related]
11. Down-regulation of BMAL1 by MiR-494-3p Promotes Hepatocellular Carcinoma Growth and Metastasis by Increasing GPAM-mediated Lipid Biosynthesis.
Yang Y; Yang T; Zhao Z; Zhang H; Yuan P; Wang G; Zhao Z; An J; Lyu Z; Xing J; Li J
Int J Biol Sci; 2022; 18(16):6129-6144. PubMed ID: 36439870
[TBL] [Abstract] [Full Text] [Related]
12. A novel model based on necroptosis-related genes for predicting immune status and prognosis in glioma.
Yuan YS; Jin X; Chen L; Liao JM; Zhang Y; Yu KW; Li WK; Cao SW; Huang XZ; Kang CM
Front Immunol; 2022; 13():1027794. PubMed ID: 36389690
[TBL] [Abstract] [Full Text] [Related]
13. Mitochondria-targeting nano therapy altering IDH2-mediated ezh2/EZH1 interaction as precise epigenetic regulation in glioblastoma.
Kaundal B; Karmakar S; Roy Choudhury S
Biomater Sci; 2022 Sep; 10(18):5301-5317. PubMed ID: 35917200
[TBL] [Abstract] [Full Text] [Related]
14. Whole-transcriptome sequencing identifies neuroinflammation, metabolism and blood-brain barrier related processes in the hippocampus of aged mice during perioperative period.
Suo Z; Yang J; Zhou B; Qu Y; Xu W; Li M; Xiao T; Zheng H; Ni C
CNS Neurosci Ther; 2022 Oct; 28(10):1576-1595. PubMed ID: 35899365
[TBL] [Abstract] [Full Text] [Related]
15. A tumor suppressor role for ezh2 in diffuse midline glioma pathogenesis.
Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
[TBL] [Abstract] [Full Text] [Related]
16. Loss of H3K27 Trimethylation Promotes Radiotherapy Resistance in Medulloblastoma and Induces an Actionable Vulnerability to BET Inhibition.
Gabriel N; Balaji K; Jayachandran K; Inkman M; Zhang J; Dahiya S; Goldstein M
Cancer Res; 2022 May; 82(10):2019-2030. PubMed ID: 35315927
[TBL] [Abstract] [Full Text] [Related]
17. The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.
Damanskienė E; Balnytė I; Valančiūtė A; Alonso MM; Preikšaitis A; Stakišaitis D
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216113
[TBL] [Abstract] [Full Text] [Related]
18. ezh2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects.
Paskeh MDA; Mehrabi A; Gholami MH; Zabolian A; Ranjbar E; Saleki H; Ranjbar A; Hashemi M; Ertas YN; Hushmandi K; Mirzaei S; Ashrafizadeh M; Zarrabi A; Samarghandian S
Biomed Pharmacother; 2022 Feb; 146():112532. PubMed ID: 34906772
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of an ezh2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
[TBL] [Abstract] [Full Text] [Related]
20. The Pivotal Immunomodulatory and Anti-Inflammatory Effect of Histone-Lysine N-Methyltransferase in the Glioma Microenvironment: Its Biomarker and Therapy Potentials.
Richard SA; Eugene KD
Anal Cell Pathol (Amst); 2021; 2021():4907167. PubMed ID: 34745848
[TBL] [Abstract] [Full Text] [Related]
[Next]
